To assess the safety and tolerability and early proof of efficacy of TAK-018 in patients with Crohn’s Disease who are planning to undergo surgery to remove the diseased ileo-cecal region of the bowel.

To evaluate the dose-response relationship of two doses of etrasimod versus placebo as induction therapy in participants with moderately to severely active Crohn’s disease.

The purpose of the study is to evaluate the safety and effectiveness of the study medicine in adults with ulcerative colitis.

Primary objective: To compare clinical efficacy by evaluating the clinical response to CBP-307 (P.O. for 12 consecutive weeks) versus placebo in subjects with moderate to severe UC

The purpose of the LATTICE-CD is to evaluate how well an oral investigational drug (called BMS- 986165) works and how safe it is for patients with moderately to severely active Crohn’s disease.

• We are conducting interviews with adults who have been clinically diagnosed with Ulcerative Colitis (UC) that is currently moderately-to-severely active based on clinician assessment.
• The focus of the interviews will be to gain a better understanding of the participant's experience living with ulcerative colitis, including what symptoms are most important to them and how these symptoms may impact their day-to-day life.

• To evaluate the effect of the prebiotic fiber inulin on the microbiome of children with IBD who have subclinical disease activity (patients with no symptoms but elevated fecal calprotectin)
• To evaluate the efficacy of the prebiotic fiber inulin in reducing gut inflammation (fecal calprotectin) in IBD

The study objectives are to: 1) assess the safety of oral administration of EcoActive (twice daily, for 15 days) in patients with clinically inactive Crohn’s disease having Adherent Invasive Escherichia coli (AIEC) present in their stools; and, 2) evaluate changes in AIEC incidence and levels in stools of patients receiving treatment versus placebo-treated controls.

The purpose of this study is to test whether a non-invasive dietary intervention during the last trimester of pregnancy can beneficially shift the microbiome, or the bacterial flora of the body, in patients with Crohn’s disease and in their babies. Crohn's disease, a type of inflammatory bowel disease, is a chronic condition of the gastrointestinal tract that is associated with an imbalance in the gut microbiome. Diet may play a role in the development and treatment of Crohn's disease. Accumulating evidence suggests that maternal health and diet during pregnancy and early life have an impact on the baby’s microbiome composition and immune system development, with long-term health consequences, including establishing risk of developing Crohn's disease and other immune-mediated diseases. By changing the maternal microbiome during pregnancy through diet, we hope to be able to promote healthier immune system development in infants born to mothers with Crohn's disease.

We are conducting interviews with both caregivers of patients with CD and patients with CD between the ages of 5 and 17 years. Through these interviews, we will identify and explore the most important symptoms of CD experienced by children and adolescents. We want to understand how symptoms impact their lives and identify the specific language patients and their caregivers use to describe CD symptoms. With this data, we will create a conceptual model of CD, which will be used to develop a measure for Eli Lilly's clinical trials.